No Data
No Data
Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK): recently received the approval notice for the supplementary application of diazepam tablets.
On September 13th, Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) announced that recently, Xinhua Pharmaceutical has received the approval notice for the transfer of the marketing authorization holder for Diazepam Tablets issued by the National Medical Products Administration.
Shandong Xinhua Pharmaceutical (00719) has received the approval and issuance of the National Medical Products Administration for the clonazepam tablets 'Supplementary Application Approval Notice for Pharmaceutical Products'.
Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced that recently, Shandong Xinhua Pharmaceutical Co., Ltd. (hereinafter referred to as "Shandong Xinhua Pharmaceutical")...
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Shandong Xinhua Secures Key Drug Application Approval
[HK Stock Connect] Shandong Xinhua Pharmaceutical Co., Ltd. (00719): The approval application for the transfer of Isoketamine Hydrochloride Injection has been approved by the National Medical Products Administration.
Jinwu Finance News | Shandong Xinhua Pharmaceutical Co., Ltd. (00719) announced that it has received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration for the transfer of the market approval holder of Ketotifen Injection (hereinafter referred to as 'the Product'). According to the announcement, Ketotifen and its metabolites improve blood rheology characteristics by reducing blood viscosity. In patients with chronic peripheral arterial diseases, it can increase blood flow to the affected microcirculation and improve tissue oxygenation. It is suitable for peripheral arterial diseases (intermittent claudication or rest pain) and inner ear circulation disorders, which are covered by the National Basic Medical Insurance law.
No Data
No Data
whqqq : Will more capital flow into the Hong Kong market after the delisting crisis?
HopelessChi whqqq : future is solid red. must be some amazing news crashing the future of HSI/HST
whqqq HopelessChi : What's the bad news?
海纳百川 whqqq : It will take longer for the market to recover; currently, it is still mainly bearish
whqqq 海纳百川 : OKAY...Thank you for your answer